P418 Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.